Best Penny Stocks To Follow Now – September 9th

SUNation Energy, Future FinTech Group, OLB Group, MGN, and Cypherpunk Technologies are the five Penny stocks to watch today, according to MarketBeat’s stock screener tool. Penny stocks are shares of small, often emerging companies that trade at very low prices, typically below $5 per share, although definitions can vary. They are generally less liquid and less regulated than larger-company stocks, making them highly volatile and potentially susceptible to fraud, but they may also offer significant—though highly speculative—growth potential. These companies had the highest dollar trading volume of any Penny stocks within the last several days.

SUNation Energy (SUNE)

Future FinTech Group (FTFT)

Future FinTech Group Inc., through its subsidiaries, operates online shopping platforms in People’s Republic of China. It operates in three segments: Supply Chain Financing Service and Trading Business, Asset Management Service, and Others. The company offers cross-border money transfer service, brokerage and investment banking, and cryptocurrency mining farm business.

OLB Group (OLB)

The OLB Group, Inc. is a diversified fintech e-commerce merchant services provider and Bitcoin crypto mining enterprise. The Company’s eCommerce platform delivers e-commerce services for a digital commerce solution to over 10,500 merchants in all 50 states. The Company’s wholly owned subsidiary, DMINT, Inc, is engaged in the mining of Bitcoin utilizing low carbon natural gas with over 1,000 application-specific integrated circuit (ASIC)-based S19j Pro 96T mining computers.

MGN (MGN)

Megan Holdings is a company principally engaged in the development, construction and maintenance of aquaculture farms and related works. Megan Holdings is based in Malaysia.

Cypherpunk Technologies (CYPH)

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.